PHENOXYBENZAMINE HCL

Phenoxybenzamine HCl is an irreversible alpha‑adrenergic antagonist that reduces vascular resistance and blood pressure. It is used for pheochromocytoma management and certain autonomic dysfunctions. Side effects include orthostatic hypotension, tachycardia, nasal congestion, fatigue, and ejaculation disorders.

SKU: 344be3afccec Category: Tag:

Product Description


Mechanism of Action

PHENOXYBENZAMINE HCL (ID 27089) demonstrates a broad, multi‑layer biochemical activity profile affecting enzyme‑driven catalytic pathways, receptor‑regulated signalling systems, mitochondrial bioenergetics, redox‑state equilibrium, ion‑channel behaviour, cytoskeletal integrity and transcription‑factor regulatory networks. Its structural features indicate potential interactions with catalytic residues, allosteric protein domains, membrane‑bound receptors and intracellular signalling intermediates, enabling influence over phosphorylation kinetics, Ca²⁺/cAMP/IP₃/DAG‑mediated second‑messenger systems, ATP turnover, ROS buffering and mitochondrial respiratory‑chain performance.

Depending on concentration and biological conditions, PHENOXYBENZAMINE HCL may modulate metabolic flux distribution, alter mitochondrial membrane potential, influence chromatin accessibility, impact vesicular trafficking dynamics and reshape gene‑expression patterns relevant to survival, inflammation, apoptosis, autophagy, metabolic adaptation and redox‑stress response.

Benefits and Advantages

This compound is widely used across advanced biochemical, pharmacological and mechanistic research domains, including:

  • Receptor–ligand interaction studies and affinity‑mapping
  • Enzyme‑kinetic pathway deconstruction and catalytic‑domain profiling
  • Mitochondrial‑function analysis and ATP‑flux/oxidative‑stress modelling
  • Multi‑omics integration (transcriptomics, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal‑structure and membrane‑dynamics research
  • Autophagy, apoptosis, necroptosis and ferroptosis signalling investigations
  • SAR (structure–activity relationship) profiling and compound‑optimisation workflows
  • Pharmacodynamic modelling, threshold‑activation mapping and dose–response scaling

Side Effects and Risks

Laboratory‑observed or predicted risks include:

  • Oxidative imbalance and excessive ROS accumulation
  • Mitochondrial overload or respiratory‑chain suppression
  • Dysregulation of Na⁺/K⁺/Ca²⁺ ion‑channel homeostasis
  • Unintended receptor cross‑talk or inhibitory interference
  • Cytoskeletal destabilisation and membrane‑integrity disruption
  • Dose‑dependent cytotoxicity with apoptosis/autophagy activation
  • Transcriptional instability or epigenetic disturbance
  • Inflammatory signalling activation via NF‑κB, MAPK or JNK pathways

Use strictly within controlled laboratory environments under appropriate biosafety protocols.

Datasheet


Molecular Formula

C18H22ClNO·HCl

Molecular Weight

340.3 g/mol

CAS Number

63-92-3

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

less than 0.1 mg/mL at 65.3 °F (NTP, 1992)

Purity

Purity information is available upon request (COA).

Synonym

Phenoxybenzamine hydrochloride; 63-92-3; Phenoxybenzamine Hcl; Dibenzyline hydrochloride; Dibenzyline chloride

IUPAC/Chemical Name

N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine;hydrochloride

InChl Key

VBCPVIWPDJVHAN-UHFFFAOYSA-N

InChl Code

InChI=1S/C18H22ClNO.ClH/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17;/h2-11,16H,12-15H2,1H3;1H

References

https://pubchem.ncbi.nlm.nih.gov/compound/5284441;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download